ESMO Expert Commentary | Professor Jin Yang: From Design Rationale to the Clinical Landscape — Advancing ADC Therapy for HER2-Low Breast Cancer
The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. At the meeting, several major studies in HER2-low breast cancer reported updated results. In particular, the presentation of large phase III clinical trial data for several novel HER2 ADCs sparked extensive discussion among experts. These findings not only offer new hope to patients but also prompt a closer examination of the relationship between different drug design strategies and clinical efficacy.









